The MDD Pipeline: New Mechanisms Beyond the Monoamine Model

"The MDD Pipeline: New Mechanisms Beyond the Monoamine Model" takes up the question of whether a crowded pipeline will change practice.

Dr. Alva lays out a pipeline finally moving somewhere genuinely new, spanning psychedelics, channel openers, thyroid supplementation, GLP-1 receptor agonists, and neuromodulation. He asks Dr. DeBattista what excites him most and what has the evidence to reach the forefront.

Dr. DeBattista welcomes the breadth of new targets and explains why the field needs them. Depression is heterogeneous, with different biologic drivers operating in different people, so a single pathway was never going to be enough. He then tempers his own enthusiasm with three decades of experience. Nearly every time the field deviated from the monoamine model, the result disappointed. He audits the record aloud. There is a GABA-A receptor modulator. Work on NMDA showed that ketamine's effects could be blocked, pointing toward opioid involvement, but the NMDA analogs failed reliably. Opioid agents were studied, and more recently his group studied tianeptine, which is banned in many countries because of its abuse liability. Sigma-1 has not delivered either. Dextromethorphan does many things at once, but pure sigma-1 agents that were studied failed.

That pattern leads Dr. DeBattista to a hypothesis he finds uncomfortable but persuasive. It may not be a single action that produces benefit, but the combination, the dirty mixture of effects. He points to the long history of dirty drugs that work, including MAOIs. He notes his colleagues at Stanford are working on better ways of targeting TMS. Then he offers the sharpest version of the argument. The most successful treatment remains ECT, which could not possibly be dirtier, hits everything, and still works when other strategies fail. He closes with calibrated optimism. He is hopeful some of these will pan out, but history suggests most will not, and the ones that succeed will likely succeed for reasons nobody anticipated.

The next episode in this series, "Shared Decision-Making in MDD Treatment Across the Lifespan," features Dr. Shirikjian and Dr. Clayton on what patients actually want from treatment.